HomeTrialNCT06593522
🔬NCT06593522Phase 2RECRUITING

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

Study Summary

The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment200 participants
Primary Completion
Lead SponsorAmgen
Data Retrieved2026-04-13 18:29:34.157155+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.